← board
DNA
distress 1/10 · well-funded / low risk$7.790%today-52% from 52w high
Revenue
$19M
Liquidity
$399M
Runway
2.4 yrs
Shares 1y
—
Price & events
-27.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.4%
1D
-6.0%
1W
-12.0%
1M
+1.2%
3M
-22.2%
6M
-44.9%
1Y
-35.3%
2Y
-98.0%
5Y
-98.1%
All
Overview
- Volume
- 99.46K
- 52 Week Range
- $5.48 – $16.14
- Float Shares
- 47.85M
- Short %
- 10.00%
- % Held by Insiders
- 4.60%
- % Held by Institutions
- 68.68%
- RVOL
- 0.10x
- Beta
- 1.78
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 3
- 2026-08-06earningsEarningsEarnings releaseyahoo
- 2024-09-03fda agreementGinkgo regains compliance with NYSE minimum price criteria for common stock.SEC 8-K
- 2024-09-03warning letterNYSE notified Ginkgo to delist warrants due to abnormally low trading price.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
Shares out: — · 0 offerings/1y · 0 PIPEs
- none
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2026-03-12BTIGSell
- 2026-01-08TD CowenBuy
- 2025-08-25BTIGSell
- 2024-09-20TD CowenBuy
- 2024-08-23BTIGSell
- 2024-07-09Goldman SachsSell
Competitors
- none identified
Recent news
- 2026-07-20Ginkgo Bioworks (NYSE: DNA) CFO logs RSU vesting and tax sell-to-cover - Stock Titan
- 2026-07-20Ginkgo Bioworks (DNA) 10K Form and Latest SEC Filings 2026 - MarketBeat
- 2026-07-18Form 144 Ginkgo Bioworks Holdings For: 17 July By Investing.com - Investing.com Nigeria
- 2026-07-17Ginkgo Bioworks (NYSE: DNA) insider Steve Coen plans Class A stock sale - Stock Titan
- 2026-07-13Responsive Playbooks and the DNA Inflection - Stock Traders Daily
- 2026-07-09Ginkgo Bioworks Holdings' Stock Sinks To US$9.07, But Insiders Sold Even Lower - simplywall.st
- 2026-07-02Understanding the Setup: (DNA) and Scalable Risk - Stock Traders Daily
- 2026-06-28Ginkgo Bioworks (DNA) Q1 2026 Earnings: EPS Misses Estimates, Stock Surges Over 7% - Post-Earnings Drift - dars.gov.et
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.